The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Ballal Rahul D. since 2020.
This trader's CIK number is 1805097.
At the time of last reporting, Ballal Rahul D. was the Director of Agios Pharmaceuticals, Inc.. (stock ticker symbol AGIO).
Also see all insider trading activities at Agios Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | AGIO | 0 | $0 | 0 | $0 | 4,422 | $0 |
| 2024 | AGIO | 0 | $0 | 20,000 | $1,122,050 | 25,690 | $519,798 |
| 2023 | AGIO | 0 | $0 | 0 | $0 | 2,302 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | ELVN | 0 | $0 | 97,420 | $2,267,727 | 97,420 | $1,311,060 |
| 2023 | ELVN | 0 | $0 | 44,174 | $197,365 | 0 | $0 |
| 2020 | ELVN | 0 | $0 | 5,000 | $125,000 | 5,000 | $15,749 |
1. Agios Pharmaceuticals, Inc. (AGIO)
2. Enliven Therapeutics, Inc. (ELVN)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-11 | AGIO | Option Ex | 2,302 | .00 | 0 |
| 2025-06-20 | AGIO | Option Ex | 2,120 | .00 | 0 |
| 2024-11-07 | AGIO | Option Ex | 10,000 | 25.99 | 259,899 |
| 2024-11-08 | AGIO | Option Ex | 10,000 | 25.99 | 259,899 |
| 2024-11-07 | AGIO | Sale | 10,000 | 53.87 | 538,650 |
| 2024-11-08 | AGIO | Sale | 10,000 | 58.34 | 583,400 |
| 2024-08-11 | AGIO | Option Ex | 2,302 | .00 | 0 |
| 2024-06-13 | AGIO | Option Ex | 3,388 | .00 | 0 |
| 2023-08-11 | AGIO | Option Ex | 2,302 | .00 | 0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-10-08 | ELVN | Sale | 10,420 | 28.17 | 293,562 |
| 2024-10-08 | ELVN | Option Ex | 10,420 | 12.60 | 131,292 |
| 2024-04-10 | ELVN | Option Ex | 13,600 | 12.60 | 171,360 |
| 2024-04-11 | ELVN | Option Ex | 53,400 | 16.14 | 861,876 |
| 2024-04-10 | ELVN | Sale | 13,600 | 21.01 | 285,749 |
| 2024-04-11 | ELVN | Sale | 53,400 | 24.45 | 1,305,469 |
| 2024-04-04 | ELVN | Option Ex | 3,485 | 12.60 | 43,911 |
| 2024-04-04 | ELVN | Sale | 3,485 | 19.15 | 66,730 |
| 2024-04-01 | ELVN | Option Ex | 3,237 | 9.06 | 29,327 |
| 2024-04-01 | ELVN | Sale | 3,237 | 19.08 | 61,758 |
| 2024-03-20 | ELVN | Option Ex | 13,278 | 5.52 | 73,294 |
| 2024-03-20 | ELVN | Sale | 13,278 | 19.16 | 254,459 |
| 2023-02-22 | IMRA | Sale | 32,861 | 4.66 | 153,132 |
| 2023-01-30 | IMRA | Sale | 11,313 | 3.91 | 44,233 |
| 2020-12-17 | IMRA | Sale | 4,999 | 25.00 | 124,975 |
| 2020-12-17 | IMRA | Option Ex | 4,999 | 3.15 | 15,746 |
| 2020-12-14 | IMRA | Option Ex | 1 | 3.15 | 3 |
| 2020-12-14 | IMRA | Sale | 1 | 25.00 | 25 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Ballal Rahul D. (Director of Agios Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.